DDInter843 DDInter1628
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Griseofulvin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Griseofulvin {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Griseofulvin {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is regulated by {v} (Gene) NPDC1
NPDC1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Griseofulvin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Griseofulvin {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is regulated by {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Griseofulvin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) upregulates {v} (Gene) MAP3K7
MAP3K7 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Griseofulvin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Dolutegravir {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Griseofulvin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Bexarotene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Griseofulvin {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is regulated by {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Griseofulvin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Mirabegron {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Griseofulvin (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Griseofulvin (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is regulated by NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Ruxolitinib (Compound)
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Griseofulvin (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is regulated by JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) upregulates MAP3K7 (Gene) and MAP3K7 (Gene) is bound by Ruxolitinib (Compound)
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Ruxolitinib (Compound)
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Griseofulvin (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is regulated by PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)